A new iMetaMed review positions cysteine peptidases—such as cathepsins B, S, L, and X—as master switches that regulate antigen presentation and tumor immune evasion. By mapping how lysosomal enzymes shape both immune visibility and resistance programs, the paper frames cysteine peptidases as promising targets for combination cancer immunotherapy development.